ASO Author Reflections: Neoadjuvant Systemic Therapy and Nodal Management in cT1-2 N0 Triple-Negative Breast Cancer.
作者信息
Cortina Chandler S, Rogers Christine C, Teshome Mediget
机构信息
Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Medical College of Wisconsin Cancer Center, Milwaukee, WI, USA.
出版信息
Ann Surg Oncol. 2024 May;31(5):3196-3197. doi: 10.1245/s10434-024-15020-6. Epub 2024 Feb 10.
Abstract
摘要
相似文献
1
ASO Author Reflections: Neoadjuvant Systemic Therapy and Nodal Management in cT1-2 N0 Triple-Negative Breast Cancer.
Ann Surg Oncol. 2024 May;31(5):3196-3197. doi: 10.1245/s10434-024-15020-6. Epub 2024 Feb 10.
2
ASO Author Reflections: Sequence of Treatment in Clinically Node-Negative T1 Triple-Negative Breast Cancer.
Ann Surg Oncol. 2023 Dec;30(13):8455-8456. doi: 10.1245/s10434-023-14122-x. Epub 2023 Aug 11.
3
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
J Am Coll Surg. 2017 Apr;224(4):688-694. doi: 10.1016/j.jamcollsurg.2016.12.036. Epub 2017 Jan 13.
4
Nodal positivity in patients with clinically and radiologically node-negative breast cancer treated with neoadjuvant chemotherapy: multicentre collaborative study.
Br J Surg. 2024 Jan 3;111(1). doi: 10.1093/bjs/znad401.
5
ASO Author Reflections: Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer: Is It Oncologically Safe?
Ann Surg Oncol. 2020 Dec;27(Suppl 3):707-708. doi: 10.1245/s10434-020-08954-0. Epub 2020 Jul 31.
6
ASO Author Reflections: The Pursuit of Eliminating Surgery after Neoadjuvant Systemic Therapy in Breast Cancer Patients.
Ann Surg Oncol. 2021 Jun;28(6):3254-3255. doi: 10.1245/s10434-020-09324-6. Epub 2020 Dec 10.
7
Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.
Ann Surg Oncol. 2019 Nov;26(12):3902-3909. doi: 10.1245/s10434-019-07643-x. Epub 2019 Jul 29.
8
ASO Author Reflections: Omission of Axillary Lymph Node Dissection for Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy: Not Ready for Primetime?
Ann Surg Oncol. 2020 Dec;27(Suppl 3):869-870. doi: 10.1245/s10434-020-08966-w. Epub 2020 Jul 31.
9
ASO Author Reflections: Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients Can Stop After Removal of Three Lymph Nodes.
Ann Surg Oncol. 2020 Dec;27(Suppl 3):848-849. doi: 10.1245/s10434-020-08874-z. Epub 2020 Jul 21.
10
Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Breast Cancer. 2019 May;26(3):373-377. doi: 10.1007/s12282-018-00934-3. Epub 2019 Jan 21.
引用本文的文献
1
Neoadjuvant chemotherapy for breast cancer in Italy: A Senonetwork analysis of 37,215 patients treated from 2017 to 2022.
Breast. 2024 Dec;78:103790. doi: 10.1016/j.breast.2024.103790. Epub 2024 Aug 30.
2
Shifting neoadjuvant chemotherapy treatment paradigms for breast cancer and its impact on axillary nodal management for clinically node-negative patients.
Gland Surg. 2024 Jul 30;13(7):1154-1158. doi: 10.21037/gs-24-159. Epub 2024 Jul 22.
本文引用的文献
1
Does Neoadjuvant Chemotherapy in Clinical T1-T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery?
Ann Surg Oncol. 2024 May;31(5):3128-3140. doi: 10.1245/s10434-024-14914-9. Epub 2024 Jan 25.
2
National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial.
Breast Cancer Res Treat. 2024 Jan;203(2):317-328. doi: 10.1007/s10549-023-07114-8. Epub 2023 Oct 20.
3
Is Axillary Radiation not Inferior to Axillary Dissection for Sentinel Lymph Node-Positive Breast Cancer After Neoadjuvant Chemotherapy?
Ann Surg Oncol. 2022 Mar;29(3):1526-1527. doi: 10.1245/s10434-021-10830-4. Epub 2021 Oct 20.
4
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
5
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.
Zotero 插件